The Anti Epilepsy Drugs Market is expected to register a CAGR of 4.7% from 2025 to 2031, with a market size expanding from US$ XX million in 2024 to US$ XX Million by 2031.
The Anti Epilepsy Drugs Market report covers analysis by Treatment (First Generation Anti-epileptics, Second Generation Anti-epileptics, Third Generation Anti-epileptics); Channel of Distribution (Hospital Pharmacies, Retail Pharmacies, Others), and Geography (North America, Europe, Asia Pacific, and South and Central America). The global analysis is further broken-down at regional level and major countries. The report Offers the Value in US$ for the above analysis and segments.
Purpose of the ReportThe report Anti Epilepsy Drugs Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:
- Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
- Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
- Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.
Anti Epilepsy Drugs Market Segmentation
Treatment- First Generation Anti-epileptics
- Second Generation Anti-epileptics
- Third Generation Anti-epileptics
- Hospital Pharmacies
- Retail Pharmacies
Strategic Insights
Anti Epilepsy Drugs Market Growth Drivers- Increasing Prevalence of Epilepsy: Epilepsy is one of the most prevailing neurological disorders affecting millions worldwide. Current research in genetic and environmental factors due to an increase in the prevalence of epilepsy is increasing demand for anti-epilepsy drugs. More patients diagnosed with epilepsy create a need for effective methods of treatment, hence driving this market upward.
- Increasing awareness and earlier diagnosis: Increased awareness of the symptoms of epilepsy and early diagnosis are essentially driving the growth of the market. As awareness about the disorder increases and understanding of it improves, the patients are being diagnosed earlier and are receiving treatment beforehand, which is boosting the demand for AEDs. SK Biopharmaceuticals, a South Korean firm, in July 2023 received regulatory approval in Canada to market its newly developed epilepsy drug, Cenobamate, under the product name Xcopri to further boost sales in the country. Health education of the public and community-based campaigns that create awareness about epilepsy-related conditions have increased the reporting of episodes and related disorders to healthcare providers.
- Innovations in Drug Development: Some crucial drivers for this market include ongoing research in the development of more potent and more targeted AEDs within the pharmaceutical industry. In March 2024, the Children's Hospital of Philadelphia approved The United States Food and Drug Administration to treat the use of the cannabis-derived Epidiolex for epilepsy in neurology. Developments related to new formulations of drugs, designing personal or personalized treatment modalities, or better improvement upon available drugs as side effect reducer drives the higher demand for more new anti-epileptic drugs.
- Shift Toward Personalized Medicine: Personalized medicine is becoming a significant trend in the treatment of epilepsy. With a better understanding of genetic factors associated with epilepsy and their increasing tendency to drugs based on an individual's genetic profile, this new approach promises a more effective treatment with fewer side effects, hence an improved overall patient experience and increased adherence to treatment.
- Increased Demand for Novel AEDs: A new trend in the development and approval of new anti-epilepsy drugs has been observed. UCB showed commitment to its efforts of transforming epilepsy care in December 2023. While attending the AES Annual Meeting, the company managed to release up to 29 studies including the four late breaks. These are specifically targeted at those types of epilepsy that are hard to treat using traditional drugs, such as refractory epilepsy. There is an increased demand for newer AEDs with better pharmacokinetics, fewer side effects, and greater efficacy. This trend demonstrates the industry's efforts to fill unmet needs in epilepsy care.
- Growing Preference for Long-Acting AEDs: Convenience, coupled with patient compliance, makes long-acting AEDs, requiring less number of dosages, a favorite in medical practice. Many patients suffering from epilepsy have a lifelong disease process, and any chronic disorder has the best possible outcome when therapeutic effects last as long as possible, with reduced frequency of dosage. It has led to demand for newer forms of AEDs in the market.
- Expanding pipeline of AEDs: Opportunities for further growth can also be derived through the continuous innovation of new AEDs. Companies are not only focusing on developing drugs against treatment-resistant epilepsy but are also exploring novel mechanisms of action targeted at the causative nature of epilepsy. Therefore, a greater pipeline of promising AEDs is now visible, offering some hope of improvement in patient outcomes for those whose epilepsy is no longer responding to current therapies.
- Strategic partnerships and acquisitions: Pharmaceutical companies increasingly engage in strategic partnerships and acquisitions to enhance the position of an AED provider. Collaboration in biotech organizations, academic establishments, and pharmaceutical companies would accelerate drug development, increase effectiveness in clinical experiments, and also speed up more innovative AEDs into markets. In January 2023, IAMA Therapeutics and PsychoGenics combined to investigate whether new drug candidates could be efficacious in the pre-clinical animal models of Dravet syndrome- a rare epilepsy that causes fatal complications in most children. Such engagements are opening areas for companies for product lines and competitive advantage portfolios.
- Government initiatives and funding: With epilepsy research, new initiatives of the government towards developing new anti-epilepsy drugs open up market opportunities for market players. The increased public funding on research on epilepsy drug therapy, regulatory incentives in terms of fast-track approval, orphan drug designation, and subsidies all present a relatively easier environment for the pharmaceutical industry to develop and launch AEDs.
Market Report Scope
Key Selling Points
- Comprehensive Coverage: The report comprehensively covers the analysis of products, services, types, and end users of the Anti Epilepsy Drugs Market, providing a holistic landscape.
- Expert Analysis: The report is compiled based on the in-depth understanding of industry experts and analysts.
- Up-to-date Information: The report assures business relevance due to its coverage of recent information and data trends.
- Customization Options: This report can be customized to cater to specific client requirements and suit the business strategies aptly.
The research report on the Anti Epilepsy Drugs Market can, therefore, help spearhead the trail of decoding and understanding the industry scenario and growth prospects. Although there can be a few valid concerns, the overall benefits of this report tend to outweigh the disadvantages.
REGIONAL FRAMEWORK
Have a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The major factors driving the Anti Epilepsy Drugs Market are Increasing Prevalence of Epilepsy, Increasing awareness and earlier diagnosis, and Innovations in Drug Development
The key future trends of the market are Shift Toward Personalized Medicine, Increased Demand for Novel AEDs, and Growing Preference for Long-Acting AEDs
The leading players operating in the Anti Epilepsy Drugs Market include UCB Pharma Ltd, Sanofi S.A, Valeant Pharmaceuticals International, Inc., Pfizer, Inc., Johnson and Johnson, Eisai Co., Ltd, Abbott Laboratories, Inc., Novartis AG, GlaxoSmithKline PLC.
The report can be delivered in PDF/PPT format; we can also share excel dataset based on the request.
Some of the customization options available based on the request are an additional 3–5 company profiles and country-specific analysis of 3–5 countries of your choice. Customizations are to be requested/discussed before making final order confirmation, as our team would review the same and check the feasibility.
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Anti Epilepsy Drugs Market - By Treatment
1.3.2 Anti Epilepsy Drugs Market - By Channel of Distribution
1.3.3 Anti Epilepsy Drugs Market - By Region
1.3.3.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. ANTI EPILEPSY DRUGS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PORTER'S FIVE FORCES ANALYSIS
4.2.1 Bargaining Power of Buyers
4.2.1 Bargaining Power of Suppliers
4.2.1 Threat of Substitute
4.2.1 Threat of New Entrants
4.2.1 Competitive Rivalry
4.3. EXPERT OPINIONS
5. ANTI EPILEPSY DRUGS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. ANTI EPILEPSY DRUGS MARKET - GLOBAL MARKET ANALYSIS
6.1. ANTI EPILEPSY DRUGS - GLOBAL MARKET OVERVIEW
6.2. ANTI EPILEPSY DRUGS - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. ANTI EPILEPSY DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - TREATMENT
7.1. OVERVIEW
7.2. TREATMENT MARKET FORECASTS AND ANALYSIS
7.3. FIRST GENERATION ANTI-EPILEPTICS
7.3.1. Overview
7.3.2. First Generation Anti-epileptics Market Forecast and Analysis
7.4. SECOND GENERATION ANTI-EPILEPTICS
7.4.1. Overview
7.4.2. Second Generation Anti-epileptics Market Forecast and Analysis
7.5. THIRD GENERATION ANTI-EPILEPTICS
7.5.1. Overview
7.5.2. Third Generation Anti-epileptics Market Forecast and Analysis
8. ANTI EPILEPSY DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - CHANNEL OF DISTRIBUTION
8.1. OVERVIEW
8.2. CHANNEL OF DISTRIBUTION MARKET FORECASTS AND ANALYSIS
8.3. HOSPITAL PHARMACIES
8.3.1. Overview
8.3.2. Hospital Pharmacies Market Forecast and Analysis
8.4. RETAIL PHARMACIES
8.4.1. Overview
8.4.2. Retail Pharmacies Market Forecast and Analysis
8.5. OTHERS
8.5.1. Overview
8.5.2. Others Market Forecast and Analysis
9. ANTI EPILEPSY DRUGS MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Anti Epilepsy Drugs Market Overview
9.1.2 North America Anti Epilepsy Drugs Market Forecasts and Analysis
9.1.3 North America Anti Epilepsy Drugs Market Forecasts and Analysis - By Treatment
9.1.4 North America Anti Epilepsy Drugs Market Forecasts and Analysis - By Channel of Distribution
9.1.5 North America Anti Epilepsy Drugs Market Forecasts and Analysis - By Countries
9.1.5.1 United States Anti Epilepsy Drugs Market
9.1.5.1.1 United States Anti Epilepsy Drugs Market by Treatment
9.1.5.1.2 United States Anti Epilepsy Drugs Market by Channel of Distribution
9.1.5.2 Canada Anti Epilepsy Drugs Market
9.1.5.2.1 Canada Anti Epilepsy Drugs Market by Treatment
9.1.5.2.2 Canada Anti Epilepsy Drugs Market by Channel of Distribution
9.1.5.3 Mexico Anti Epilepsy Drugs Market
9.1.5.3.1 Mexico Anti Epilepsy Drugs Market by Treatment
9.1.5.3.2 Mexico Anti Epilepsy Drugs Market by Channel of Distribution
9.2. EUROPE
9.2.1 Europe Anti Epilepsy Drugs Market Overview
9.2.2 Europe Anti Epilepsy Drugs Market Forecasts and Analysis
9.2.3 Europe Anti Epilepsy Drugs Market Forecasts and Analysis - By Treatment
9.2.4 Europe Anti Epilepsy Drugs Market Forecasts and Analysis - By Channel of Distribution
9.2.5 Europe Anti Epilepsy Drugs Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Anti Epilepsy Drugs Market
9.2.5.1.1 Germany Anti Epilepsy Drugs Market by Treatment
9.2.5.1.2 Germany Anti Epilepsy Drugs Market by Channel of Distribution
9.2.5.2 France Anti Epilepsy Drugs Market
9.2.5.2.1 France Anti Epilepsy Drugs Market by Treatment
9.2.5.2.2 France Anti Epilepsy Drugs Market by Channel of Distribution
9.2.5.3 Italy Anti Epilepsy Drugs Market
9.2.5.3.1 Italy Anti Epilepsy Drugs Market by Treatment
9.2.5.3.2 Italy Anti Epilepsy Drugs Market by Channel of Distribution
9.2.5.4 Spain Anti Epilepsy Drugs Market
9.2.5.4.1 Spain Anti Epilepsy Drugs Market by Treatment
9.2.5.4.2 Spain Anti Epilepsy Drugs Market by Channel of Distribution
9.2.5.5 United Kingdom Anti Epilepsy Drugs Market
9.2.5.5.1 United Kingdom Anti Epilepsy Drugs Market by Treatment
9.2.5.5.2 United Kingdom Anti Epilepsy Drugs Market by Channel of Distribution
9.2.5.6 Rest of Europe Anti Epilepsy Drugs Market
9.2.5.6.1 Rest of Europe Anti Epilepsy Drugs Market by Treatment
9.2.5.6.2 Rest of Europe Anti Epilepsy Drugs Market by Channel of Distribution
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Anti Epilepsy Drugs Market Overview
9.3.2 Asia-Pacific Anti Epilepsy Drugs Market Forecasts and Analysis
9.3.3 Asia-Pacific Anti Epilepsy Drugs Market Forecasts and Analysis - By Treatment
9.3.4 Asia-Pacific Anti Epilepsy Drugs Market Forecasts and Analysis - By Channel of Distribution
9.3.5 Asia-Pacific Anti Epilepsy Drugs Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Anti Epilepsy Drugs Market
9.3.5.1.1 Australia Anti Epilepsy Drugs Market by Treatment
9.3.5.1.2 Australia Anti Epilepsy Drugs Market by Channel of Distribution
9.3.5.2 China Anti Epilepsy Drugs Market
9.3.5.2.1 China Anti Epilepsy Drugs Market by Treatment
9.3.5.2.2 China Anti Epilepsy Drugs Market by Channel of Distribution
9.3.5.3 India Anti Epilepsy Drugs Market
9.3.5.3.1 India Anti Epilepsy Drugs Market by Treatment
9.3.5.3.2 India Anti Epilepsy Drugs Market by Channel of Distribution
9.3.5.4 Japan Anti Epilepsy Drugs Market
9.3.5.4.1 Japan Anti Epilepsy Drugs Market by Treatment
9.3.5.4.2 Japan Anti Epilepsy Drugs Market by Channel of Distribution
9.3.5.5 South Korea Anti Epilepsy Drugs Market
9.3.5.5.1 South Korea Anti Epilepsy Drugs Market by Treatment
9.3.5.5.2 South Korea Anti Epilepsy Drugs Market by Channel of Distribution
9.3.5.6 Rest of Asia-Pacific Anti Epilepsy Drugs Market
9.3.5.6.1 Rest of Asia-Pacific Anti Epilepsy Drugs Market by Treatment
9.3.5.6.2 Rest of Asia-Pacific Anti Epilepsy Drugs Market by Channel of Distribution
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Anti Epilepsy Drugs Market Overview
9.4.2 Middle East and Africa Anti Epilepsy Drugs Market Forecasts and Analysis
9.4.3 Middle East and Africa Anti Epilepsy Drugs Market Forecasts and Analysis - By Treatment
9.4.4 Middle East and Africa Anti Epilepsy Drugs Market Forecasts and Analysis - By Channel of Distribution
9.4.5 Middle East and Africa Anti Epilepsy Drugs Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Anti Epilepsy Drugs Market
9.4.5.1.1 South Africa Anti Epilepsy Drugs Market by Treatment
9.4.5.1.2 South Africa Anti Epilepsy Drugs Market by Channel of Distribution
9.4.5.2 Saudi Arabia Anti Epilepsy Drugs Market
9.4.5.2.1 Saudi Arabia Anti Epilepsy Drugs Market by Treatment
9.4.5.2.2 Saudi Arabia Anti Epilepsy Drugs Market by Channel of Distribution
9.4.5.3 Rest of Middle East and Africa Anti Epilepsy Drugs Market
9.4.5.3.1 Rest of Middle East and Africa Anti Epilepsy Drugs Market by Treatment
9.4.5.3.2 Rest of Middle East and Africa Anti Epilepsy Drugs Market by Channel of Distribution
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Anti Epilepsy Drugs Market Overview
9.5.2 South and Central America Anti Epilepsy Drugs Market Forecasts and Analysis
9.5.3 South and Central America Anti Epilepsy Drugs Market Forecasts and Analysis - By Treatment
9.5.4 South and Central America Anti Epilepsy Drugs Market Forecasts and Analysis - By Channel of Distribution
9.5.5 South and Central America Anti Epilepsy Drugs Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Anti Epilepsy Drugs Market
9.5.5.1.1 Brazil Anti Epilepsy Drugs Market by Treatment
9.5.5.1.2 Brazil Anti Epilepsy Drugs Market by Channel of Distribution
9.5.5.2 Argentina Anti Epilepsy Drugs Market
9.5.5.2.1 Argentina Anti Epilepsy Drugs Market by Treatment
9.5.5.2.2 Argentina Anti Epilepsy Drugs Market by Channel of Distribution
9.5.5.3 Rest of South and Central America Anti Epilepsy Drugs Market
9.5.5.3.1 Rest of South and Central America Anti Epilepsy Drugs Market by Treatment
9.5.5.3.2 Rest of South and Central America Anti Epilepsy Drugs Market by Channel of Distribution
10. INDUSTRY LANDSCAPE
10.1. MERGERS AND ACQUISITIONS
10.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
10.3. NEW PRODUCT LAUNCHES
10.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
11. ANTI EPILEPSY DRUGS MARKET, KEY COMPANY PROFILES
11.1. UCB PHARMA LTD
11.1.1. Key Facts
11.1.2. Business Description
11.1.3. Products and Services
11.1.4. Financial Overview
11.1.5. SWOT Analysis
11.1.6. Key Developments
11.2. SANOFI S.A
11.2.1. Key Facts
11.2.2. Business Description
11.2.3. Products and Services
11.2.4. Financial Overview
11.2.5. SWOT Analysis
11.2.6. Key Developments
11.3. VALEANT PHARMACEUTICALS INTERNATIONAL, INC.
11.3.1. Key Facts
11.3.2. Business Description
11.3.3. Products and Services
11.3.4. Financial Overview
11.3.5. SWOT Analysis
11.3.6. Key Developments
11.4. PFIZER, INC.
11.4.1. Key Facts
11.4.2. Business Description
11.4.3. Products and Services
11.4.4. Financial Overview
11.4.5. SWOT Analysis
11.4.6. Key Developments
11.5. JOHNSON AND JOHNSON
11.5.1. Key Facts
11.5.2. Business Description
11.5.3. Products and Services
11.5.4. Financial Overview
11.5.5. SWOT Analysis
11.5.6. Key Developments
11.6. EISAI CO., LTD
11.6.1. Key Facts
11.6.2. Business Description
11.6.3. Products and Services
11.6.4. Financial Overview
11.6.5. SWOT Analysis
11.6.6. Key Developments
11.7. ABBOTT LABORATORIES, INC.
11.7.1. Key Facts
11.7.2. Business Description
11.7.3. Products and Services
11.7.4. Financial Overview
11.7.5. SWOT Analysis
11.7.6. Key Developments
11.8. NOVARTIS AG
11.8.1. Key Facts
11.8.2. Business Description
11.8.3. Products and Services
11.8.4. Financial Overview
11.8.5. SWOT Analysis
11.8.6. Key Developments
11.9. GLAXOSMITHKLINE PLC.
11.9.1. Key Facts
11.9.2. Business Description
11.9.3. Products and Services
11.9.4. Financial Overview
11.9.5. SWOT Analysis
11.9.6. Key Developments
11.10. SUNOVION PHARMACEUTICALS, INC
11.10.1. Key Facts
11.10.2. Business Description
11.10.3. Products and Services
11.10.4. Financial Overview
11.10.5. SWOT Analysis
11.10.6. Key Developments
12. APPENDIX
12.1. ABOUT THE INSIGHT PARTNERS
12.2. GLOSSARY OF TERMS
1. UCB Pharma Ltd
2. Sanofi S.A
3. Valeant Pharmaceuticals International, Inc.
4. Pfizer, Inc.
5. Johnson and Johnson
6. Eisai Co., Ltd
7. Abbott Laboratories, Inc.
8. Novartis AG
9. GlaxoSmithKline PLC.
10. Sunovion Pharmaceuticals, Inc
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For